Insys reaffirms Q2 revenue guidanceJun. 30, 2014 8:22 AM ET|About: Insys Therapeutics, Inc. (INSY)|By: Douglas W. House, SA News Editor Insys Therapeutics (INSY) reaffirms its Q2 revenue guidance for Subsys (Fentanyl Sublingual Spray). Sales should exceed $52M. This represents a yoy increase of 181%. The company will report its results for the quarter on August 12 before the open.